secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2025-09-24T23:59:59+00:00
Accession:  0001104659-25-092681
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palvella expands QTORIN rapamycin program into angiokeratomas, plans Phase 2 in H2 2026
--------------------------------------------------------------------------------

- No FDA-approved therapies exist for clinically significant angiokeratomas, which affect >50,000 diagnosed U.S. patients.
- Phase 2 trial of QTORIN rapamycin for angiokeratomas planned to start H2 2026; FDA meeting expected H1 2026.
- Ongoing Phase 3 SELVA study for microcystic lymphatic malformations: top-line results Q1 2026; TOIVA Phase 2 results mid-Dec 2025.
- Angiokeratomas recently classified as isolated lymphatic malformation by ISSVA in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000110465925092681/0001104659-25-092681-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000110465925092681/tm2526823d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-092681

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer